Download the 2005 pdf - UHN Research

SALUTING PARTNERS
UHN+ PARTNERS=
Recruiting
New Expertise
Dr.
Suzanne Trudel is
one of UHN’s newest
scientists, and she was recruited
through the McLaughlin Centre for
Molecular Medicine (MCMM),a
$150M “virtual centre” established in
2001 “to advance the basic biomedical
sciences of genetics and molecular
biology and translate them into new
strategies for disease diagnosis, treatment
and prevention.”
The McLaughlin Centre is itself a
partnership comprising the University
of Toronto Faculty of Medicine, the
Hospital for Sick Children, Mount
Sinai Hospital, Sunnybrook and
Women's College Health Sciences
Centre, and University Health
Network. Significant funding is
provided by the Ontario Innovation
Her research
focuses on new
drug development
for the treatment of
mature B–cell malignancies
based on
molecular targets.
Trust and the McLaughlin Foundation.
Dr. Trudel is a member of the
MCMM Program in Molecular Therapeutics,
and her research focuses on
new drug development for the treatment
of mature B–cell malignancies
based on molecular targets. Her work
has recently resulted in the validation
of a new clinical target in myeloma,
and the first clinical trial of drugs
targeting this molecule.
She did her medical training at
the University of Toronto, and was
lured back to the city, and to UHN,
after further training in the United
States. "I was attracted by the
opportunity to work at an institute
with state-of-the-art tools, worldrenowned
scientists, one of the top
clinical programs in mature B–cell
malignancies in North America and
with a vision to apply molecular
discovery to clinical care of patients .”
In recent years the UHN-McLaughlin
partnership has been successful in
recruiting two other new investigators,
Drs. Xiao-Yen Wen and Aaron
Schimmer, both part of the MCMM
Program in Molecular Therapeutics.
14 RESEARCH REPORT 2005